Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N
TRVI.OQ - Trevi Therapeutics Inc
Trevi Therapeutics Inc at Bank of America Global Healthcare Conference
May 13, 2026 / 12:15AM GMT
=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
I'll take you through it, but it's about a $6 billion-plus peak sales opportunity. So our mechanism, this is where it all starts. The drug works not only peripherally in the lung, it works along the spinal cord and the brain stem in the brain. That mediates coughing and breathing. This is a whole cough reflex arc, so being present in that whole pathway is helpful.
And to focus on our two lead indications of IPF and non-IPF. So first of all, starting off with IPF. This is a terminal condition. It's about 140,000 patients in the U.S. You probably know there's been a lot of work done around antifibrotics, which essentially slow disease progression. We're focused on the patient and what upsets the
Trustpilot
